EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Biomarkers for Prostate Cancer Bone Metastasis Detection and Prediction

Mingshuai Ying iD, Jianshui Mao, Lingchao Sheng, Hongwei Wu, Guangchao Bai, Zhuolin Zhong, Zhijun Pan

Journal of Personalized Medicine · 22.04.2023 · 13 (5) · 705

DOI: 10.3390/jpm13050705 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Personalized Medicine, online erschienen am 22.04.2023. Verfasst von Mingshuai Ying und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopaedic Surgery, The Fourth Affiliated Hospital, International Institutes of Medicine, Zhejiang University School of Medicine, Yiwu…. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 157 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Prostate cancer (PCa) causes deaths worldwide, ranking second after lung cancer. Bone metastasis (BM) frequently results from advanced PCa, affecting approximately 90% of patients, and it also often results in severe skeletal-related events. Traditional diagnostic methods for bone metastases, such as tissue biopsies and imaging, have substantial drawbacks. This article summarizes the significance of biomarkers in PCa accompanied with BM, including (1) bone formation markers like osteopontin (OPN), pro-collagen type I C-terminal pro-peptide (PICP), osteoprotegerin (OPG), pro-collagen type I N-terminal pro-peptide (PINP), alkaline phosphatase (ALP), and osteocalcin (OC); (2) bone resorption markers, including C-telopeptide of type I collagen (CTx), N-telopeptide of type I collagen (NTx), bone sialoprotein (BSP), tartrate-resistant acid phosphatase (TRACP), deoxypyridinoline (D-PYD), pyridoxine (PYD), and C-terminal pyridinoline cross-linked telopeptide of type I collagen (ICTP); (3) prostate-specific antigen (PSA); (4) neuroendocrine markers, such as chromogranin A (CgA), neuron-specific enolase (NSE), and pro-gastrin releasing peptide (ProGRP); (5) liquid biopsy markers, such as circulating tumor cells (CTCs), microRNA (miRNA), circulating tumor DNA (ctDNA), and cell-free DNA (cfDNA) and exosomes. In summary, some of these markers are already in widespread clinical use, while others still require further laboratory or clinical studies to validate their value for clinical application.

Schlagwörter

Stichwörter der Autor:innen

PSAbone formation/resorption markersbone metastasisliquid biopsyneuroendocrine markerspredictive biomarkersprostate cancer

Autor:innen und Institutionen

  • Department of Orthopaedic Surgery, The Fourth Affiliated Hospital, International Institutes of Medicine, Zhejiang University School of Medicine, Yiwu 322000, China.
  • Department of Orthopaedic Surgery, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310000, China.

ORCID-Profile: Mingshuai Ying

Zitieren

APA

Ying, M., Mao, J., Sheng, L., Wu, H., Bai, G., Zhong, Z., & Pan, Z. (2023). Biomarkers for Prostate Cancer Bone Metastasis Detection and Prediction. Journal of Personalized Medicine, 13(5), 705. https://doi.org/10.3390/jpm13050705

Vancouver

Ying M, Mao J, Sheng L, Wu H, Bai G, Zhong Z, et al. Biomarkers for Prostate Cancer Bone Metastasis Detection and Prediction. Journal of Personalized Medicine. 2023;13(5):705. doi:10.3390/jpm13050705

BibTeX
@article{Ying2023,
  author = {Ying, Mingshuai and Mao, Jianshui and Sheng, Lingchao and Wu, Hongwei and Bai, Guangchao and Zhong, Zhuolin and Pan, Zhijun},
  title = {Biomarkers for Prostate Cancer Bone Metastasis Detection and Prediction},
  journal = {Journal of Personalized Medicine},
  year = {2023},
  volume = {13},
  number = {5},
  pages = {705},
  doi = {10.3390/jpm13050705}
}
Kostenlos starten →